Study Finds Non-Opioid Drug Journavx Prescribed Off-Label for Chronic Pain More Often Than Opioids

Fifteen months after the FDA approved the first entirely new class of pain medication in over two decades, the drug is not being used exactly as regulators intended. When Vertex Pharmaceuticals launched Journavx—generically known as suzetrigine—in early 2025, the non-opioid pill was explicitly authorized for moderate-to-severe acute pain, such as the immediate aftermath of a surgery or a traumatic injury. It was heralded as a critical tool to prevent patients from ever receiving their first opioid prescription. Yet, an extensive new analysis of health records reveals a starkly different reality in American clinics. Rather than replacing opioids in emergency rooms and surgical wards, Journavx is being heavily prescribed off-label to patients suffering from long-term, intractable chronic pain conditions. The shift highlights a profound desperation among patients and pain specialists who have spent years navigating the dual crises of chronic pain and opioid addiction, searching for anything that might offer relief without the risk of chemical dependency.[1][2][3][6]

The scope of this prescribing shift was detailed in a comprehensive study published by Epic Research, which analyzed the electronic health records of more than 3.6 million adults in the United States. Researchers compared patients who received a new prescription for either Journavx or a traditional opioid between February 2025 and April 2026. The data showed that a full 33 percent of all Journavx prescriptions were written for chronic pain diagnoses. By stark contrast, only 6.7 percent of opioid prescriptions during the same period were issued for chronic pain. The numbers indicate that physicians are actively reserving the new, non-addictive medication for their long-term pain patients, while continuing to rely on established opioids for immediate, short-term surgical recovery.[1][2]

A closer look at the clinical settings where these drugs are dispensed further illustrates the divide. According to the Epic Research data, opioid prescribing remains heavily concentrated in acute-care environments. Emergency medicine and general surgery departments accounted for 64.1 percent of all new opioid prescriptions, but only 20.8 percent of Journavx prescriptions. Conversely, pain medicine specialists and orthopedic surgeons—doctors who typically manage patients longitudinally over months or years—wrote nearly 41 percent of all Journavx prescriptions, compared to a mere 3.5 percent of opioid orders. This specialty mix confirms that suzetrigine adoption is being driven by providers managing complex, ongoing pain rather than those treating sudden, temporary injuries.[1][2]

The demographics of the patients receiving the new drug also diverge significantly from traditional opioid recipients. The Epic researchers found that individuals prescribed Journavx were notably older and more likely to be female. Specifically, 43 percent of patients receiving the non-opioid medication were aged 65 or older, compared to 31.4 percent of those given opioids. Furthermore, 63.1 percent of Journavx recipients were female. This demographic profile aligns closely with the populations most frequently affected by chronic pain conditions such as osteoarthritis, fibromyalgia, and various neuropathies, further cementing the drug's emerging role as a chronic pain intervention despite its acute-pain label.[1][2]

To understand why doctors are so eager to try Journavx for chronic conditions, one must look at its novel mechanism of action. For decades, the most powerful painkillers available have been opioids, which work by binding to mu-opioid receptors in the central nervous system. While highly effective at blunting the perception of pain, opioids also trigger the release of dopamine in the brain's reward centers, creating the euphoria that drives addiction. They also depress the respiratory system, which is the primary cause of fatal overdoses. Journavx bypasses the brain entirely. It is a highly selective inhibitor of NaV1.8, a specific type of voltage-gated sodium channel found almost exclusively in peripheral pain-sensing nerves, known as nociceptors.[3][4][5]

By targeting these peripheral nerves, Journavx effectively acts as a roadblock, stopping pain signals at their source before they can travel up the spinal cord and reach the brain. Because the drug does not cross the blood-brain barrier or interact with central nervous system receptors, it carries zero risk of addiction, chemical dependency, or respiratory depression. Clinical trials demonstrated no evidence of withdrawal symptoms or drug-seeking behavior among participants. For pain specialists managing older adults—who are particularly vulnerable to the sedating and respiratory effects of opioids—a medication that isolates pain relief to the periphery represents a massive pharmacological breakthrough.[3][4][5][6]

Despite the enthusiasm, the widespread off-label use of Journavx for chronic pain ventures into medically uncertain territory. Off-label prescribing—where a physician prescribes an FDA-approved drug for an unapproved indication—is perfectly legal and common in medicine. However, it means the drug is being deployed without the rigorous, large-scale clinical trial data required to prove it actually works for that specific condition. The FDA approved Journavx based on two Phase 3 clinical trials that evaluated its efficacy over a mere 48-hour period following bunionectomies and abdominoplasties. Vertex Pharmaceuticals explicitly advises that the drug is intended for short-term use, typically up to 14 days.[2][3][5][6]

When evaluated strictly on its pain-relieving power, the clinical data for Journavx is decidedly modest. In the acute pain trials that secured its FDA approval, the drug demonstrated statistically significant superiority over a placebo. However, it failed to prove that it was any more effective than a standard, low-dose combination of hydrocodone and acetaminophen—commonly known as Vicodin. While matching the efficacy of a mild opioid without the addiction risk is a significant achievement for acute postoperative care, it raises questions about whether the drug possesses the sheer analgesic strength required to manage severe, intractable chronic pain over months or years.[2][3][4][5]

The evidence regarding Journavx's efficacy specifically for chronic pain is even less encouraging. In a Phase 2 clinical study evaluating the drug for lumbosacral radiculopathy—a common form of chronic lower back and hip pain caused by nerve compression—Journavx was essentially no better than a placebo at relieving symptoms. A recent case series published in the medical literature detailed patients with severe, cancer-related bone pain who were given a trial of suzetrigine. The highly opioid-tolerant patients experienced no meaningful improvement in their pain levels and discontinued the medication.[2][4][5]

The disconnect between the drug's modest clinical trial performance and its rapid adoption in chronic pain clinics underscores the sheer desperation within the pain management community. The aggressive push to reduce opioid prescribing over the last decade successfully lowered overdose deaths from prescription pills, but it left millions of chronic pain patients stranded without effective alternatives. Many patients were forcibly tapered off opioids and left to rely on gabapentin, antidepressants, or over-the-counter anti-inflammatories, which often carry their own severe side effects or provide inadequate relief. In this landscape, any new, non-addictive mechanism is viewed as a lifeline worth trying, even if the clinical data is still catching up.[2][4][5]

This off-label experimentation comes at a steep financial cost. Vertex Pharmaceuticals priced Journavx at a wholesale cost of $15.50 for a single 50-milligram tablet. Because the medication is taken twice daily, a standard one-week supply costs approximately $420. By comparison, a generic supply of 100 hydrocodone-acetaminophen tablets costs roughly $142. While Vertex offers patient assistance programs and savings cards for those prescribed the drug for its approved acute indications, insurance companies are notoriously reluctant to cover expensive medications for off-label uses. This dynamic forces many chronic pain patients to pay out-of-pocket or abandon the trial entirely if their initial prescription is denied by their carrier.[2]

For patients currently navigating chronic pain, the ultimate role of suzetrigine will depend on ongoing research. Vertex is actively conducting Phase 3 clinical trials evaluating the drug's efficacy for diabetic peripheral neuropathy, a chronic nerve pain condition that affects millions. If those trials succeed, the FDA could officially expand the drug's label, forcing insurance companies to cover it and providing physicians with concrete dosing guidelines for long-term use. Until then, patients should have an open conversation with their pain specialist about whether an off-label trial of Journavx makes sense for their specific condition, weighing the high out-of-pocket costs against the genuine benefit of a non-addictive alternative. The medication remains an experimental but hopeful option—a testament to the urgent need for innovation in a field that has been paralyzed by the opioid epidemic for a quarter of a century.[2][4][5]